A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of Genasense Administered as a 2-hour Intravenous Infusion to Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2012
At a glance
- Drugs Oblimersen (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 04 Apr 2012 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.